Biologic response modifiers in rheumatology: Assessment of patient satisfaction;Biothérapies en rhumatologie: Évaluation de la satisfaction des patients

Journal de Pharmacie Clinique

Volumn 23, Issue 4, 2004, Pages 209-217

  Roos, J ^a   Gaudin, P ^a   Allenet, B ^a   Pascal, C ^a   Francois P ^a   Calop, J ^a   Juvin, R ^a  

^a GRENOBLE UNIVERSITY HOSPITAL   (France)

Author keywords

Biologic response modifiers; Patient satisfaction

Indexed keywords

ADALIMUMAB; BIOLOGICAL RESPONSE MODIFIER; CYTOKINE; ETANERCEPT; INFLIXIMAB; INTERLEUKIN 1; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; TUMOR NECROSIS FACTOR ALPHA;

ADOLESCENT; ADULT; AGED; ARTICLE; BLOOD EXAMINATION; DAILY LIFE ACTIVITY; DRUG MARKETING; DRUG STORAGE; DRUG TOLERABILITY; EDUCATION PROGRAM; FEMALE; FOLLOW UP; FRANCE; FREEZING; HOSPITAL PHARMACY; HUMAN; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; PATIENT EDUCATION; PATIENT INFORMATION; PATIENT SATISFACTION; QUESTIONNAIRE; RETROSPECTIVE STUDY; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS; RHEUMATOLOGY; RISK BENEFIT ANALYSIS; SCORING SYSTEM; SELF MEDICATION; SIDE EFFECT;

EID: 12444304181     PISSN: 02911981     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Toussirot E, Wendling D. The use of TNF-alpha blocking agents in rheumatoid arthritis: an overview. Expert Opin Pharmacother 2004; 5: 581-94.
2. Fain O. TNF-alpha inhibitors. Rev Prat 2003; 53: 1989-90.
3. Blumenauer B, Judd M, Cranney A, et al. Infliximab for the treatment of rheumatoid arthritis (Cochrane Review), http: //www.cochrane.org/cochrane/ revabstr/AB003785.htm., Avril 2004.
4. Blumenauer B, Judd M, Cranney A, et al. Etanercept for the treatment of rheumatoid arthritis. (Cochrane Review). http://www. cochrane.org/cochrane/ revabstr/ab004525.htm, Avril 2004.
5. Bang LM, Keating GM. Adalimumab: a review of its use in rheumatoid arthritis. BioDrugs 2004; 18: 121-39.
6. Clark W, Jobanputra P, Barton P, Burls A. The clinical and cost-effectiveness of anakinra for the treatment of rheumatoid arthritis in adults: a systematic review and economic analysis. Heath Technol Assess 2004; 8: 1-105.
7. Vilcek J, Feldmann M. Historical review: cytokines as therapeutics and target of therapeutics. Trends Pharmacol Sci 2004; 25: 201-19.
8. Homik JE, Suarez-Almazor M. An economic approach to health care. Best Pract Res Clin Rheumatol 2004; 18: 203-18.
9. Parée F, Allenet B, Lebrun T, Pelen F, Verriere F. Les observatoires de la prescription: contexte, mise en œuvre et perspectives. Journal d'économie médicale 2000; 18: 343-8.
10. Berthelot JM, Gillard J, Guillot P, Varin S, Maugars Y, et la Société de rhumatologie de l'Ouest. Jugement de 300 rhumatologues français sur l'efficocité et la tolérance des anti-TNF alpha en décembre 2002. Congrès de la Société des rhumatologues de l'Ouest. Nantes, 2002.
11. Berthelot JM, Gillard J, Guillot P, Varin S, Mougars Y, et la Société de rhumatologie de l'Ouest. Opinions en décembre 2002 de 300 rhumatologues français quant aux coûts des troitements par anti-TNF alpha et ses conséquences. Congrès de la Société des rhumatologues de l'Ouest. Nantes, 2002.
12. Berthier N. Les techniques d'enquête: méthodes et exercices corrigés. Collection Cursus, série «sociologie». Paris: Armand Colin, 1998.
13. Sany J. Polyarthrite rhumatoïde de l'adulte: conception actuelle. Collection Pathologie Science Formation. Paris: John Libbey Eurotext, 2003.
14. Schnabel A. Disease-modifying antirheumatic drugs: enhancing efficacy by combination. Lancet 2004; 363: 670-1.
15. Perdriger AL, Combe B, Kuntz JL, et al. A French multicenter study on the efficacy and safety of infliximab in association with DMARDS other than méthotrexate. Orlando: American college of rheumatology, 2003.
16. Pascoe GC. Patient satisfaction in primary health care: a litterature review and analysis. Eval Program Plann 1983; 6: 185-210.
17. Donabedian A. The quality of care: how can it be assessed. JAMA 1988; 250: 1743-8.
18. Ware JE. The measurement and meaning of patient satisfaction. A review of recent litterature. Health Med Care Serv Rev 1998; 1: 1-15.
19. Brown SL, Greene MH, Gershon SK, Edwards ET, Braun MM. Tumor necrosis factor antagonist therapy and lymphoma development: twenty-six cases reported to the food and drug administration. Arthritis Rheum 2002; 46: 3151-8.
20. Imperato AK, Smiles S, Abramson SB. Long-term risks associated with biologic response modifiers used in rheumatic diseases. Curr Opin Rheumatol 2004; 16: 199-205.
21. Berthelot JM, Glemarec J, Guillot P, Chiffoleau A, Maugars Y, Rodat O. Informing patients about serious side effects of drugs. A 2001 survey of 341 French rheumatologists. Joint Bone Spine 2003; 70: 52-7.
22. Ankri J, Le Disert D, Henrad JC. Compartements individuels face aux médicaments. De l'observance thérapeutique à l'expérience de la maladie, analyse de la littérature. Santé publique 1995; 74: 427-41.
23. Jacobi CE, Boshuizen HC, Rupp I, Dinant HJ, Van Den Bos GA. Quality of rheumatoid arthritis care: the patient's perspective. Int J Qual Health Care 2004; 16: 73-81.